Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Genmab A/S - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GMAB
Nasdaq
8731
https://www.genmab.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Genmab A/S - ADR
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
- Apr 16th, 2024 10:24 am
Roche reports survival data for new dual-acting lymphoma drug
- Apr 15th, 2024 11:57 am
Transactions in Connection with Share Buy-back Program Genmab
- Apr 15th, 2024 8:07 am
Transactions in Connection with Share Buy-back Program
- Apr 8th, 2024 9:44 am
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover
- Apr 3rd, 2024 8:02 pm
Stocks to Watch Wednesday: Disney, Intel, Tesla, Trump Media
- Apr 3rd, 2024 5:05 pm
Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry
- Apr 3rd, 2024 11:28 am
Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio
- Apr 3rd, 2024 8:48 am
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
- Apr 3rd, 2024 5:35 am
Completion of share buy-back program
- Mar 18th, 2024 9:49 am
30 Biggest Biotechnology Companies in the World
- Mar 17th, 2024 12:50 pm
Genmab Announces Initiation of Share Buy-Back Program
- Mar 15th, 2024 12:16 pm
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Mar 13th, 2024 8:58 pm
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
- Mar 13th, 2024 8:53 pm
Passing of Genmab A/S’ Annual General Meeting
- Mar 13th, 2024 3:13 pm
Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Feb 27th, 2024 8:40 pm
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
- Feb 27th, 2024 12:45 pm
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
- Feb 23rd, 2024 10:35 pm
Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript
- Feb 15th, 2024 3:47 pm
Genmab: Growth Is Still a Better Choice
- Feb 15th, 2024 1:00 pm
Scroll